Neuroendocrine gastrointestinal tumours

Annals of Oncology

Volumn 7, Issue 5, 1996, Pages 453-463

  Oberg K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

IFN; Carcinoids; Chromogranin A; Endocrine pancreatic tumours; Neuroendocrine gastrointestinal tumours; Octreoscan; Somatostatin analogue

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DOXORUBICIN; FLUOROURACIL; OCTREOTIDE; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

CARCINOID; DIGESTIVE SYSTEM TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030036419     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010633     Document Type: Review

References (119)

1. Norheim I, Öberg K, Theodorsson-Norheim E et al. Malignant carcinoid tumors: An analysis of 103 patients with regard to tumor localization, hormone production and survival, Ann Surg 1987; 206: 115-25.
2. Eriksson B, Arnberg H, Lindgren PG et al. Neuroendocrine pancreatic tumors: Clinical presentation, biochemical and histopathological findings in 84 patients. J Int Med 1990; 228: 103-13.
3. Williams ED, Sandler M. The classification of carcinoid tumours. The Lancet 1963; 1: 238-9.
4. Wilander E, Lundqvist M, Öberg K. Gastrointestinal carcinoid tumours. Prog Histochem Cytochem 1989; 19: 1-85.
5. Wermer P. Multiple endocrine adenomatosis, multiple hormone-producing tumors, a familial syndrome. Clin Gastroenterol 1974; 3: 671-84.
6. Larsson C, Skogseid B, Öberg K et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-7.
7. Byström C, Larsson C, Blomberg C et al. Localization of the MEN 1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA 1990; 83: 1968-72.
8. Skogseid B, Eriksson B, Lundqvist G et al. Multiple endocrine neoplasia type 1: A ten-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991; 73: 281-7.
9. Zollinger RM, Ellison EC, Fabri PJ et al. Primary peptic ulceration of the jejunum associated with islet cell tumors. Twenty-five year appraisal. Ann Surg 1980; 192: 520-30.
10. Pipeleers-Marichal M, Somers G, Willems G et al. Gastrinomas in the duodenum of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322: 723-7.
11. Thorson Å, Biörck G, Björkman G et al. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusal type of cyanosis. Am Heart J 1954; 47: 795-817.
12. Grahame-Smith DG. The Carcinoid Syndrome. London: William Heineman Medical Books 1972.
13. Feldman JM. Carcinoid tumors and syndrome. Semin Oncol 1987; 14: 237.
14. Jensen RT. Zollinger-Ellison syndrome: Current concepts and management. Ann Int Med 1983; 98: 59-75.
15. Galbut DL, Markowitz AM. Insulinoma: Diagnosis, surgical management and long-term follow-up. Am J Surg 1980; 139: 682.
16. Stefanini P, Carboni M, Patrassi N et al. Beta-islet cell tumor of the pancreas: Results of a study on 1,067 cases. Surgery 1974; 75: 597.
17. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 1989; 18: 45.
18. Verner JV, Morrison AB. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 1958; 29: 529.
19. Long RG, Bryant MG, Mitchell SJ et al. Clinicopathological study of pancreatic and ganglioneuroblastoma tumors secreting vasoactive intestinal polypeptide (VIPomas). Br Med J 1981; 282: 1767.
20. Verner JV, Morrison AB. Endocrine pancreatic islet disease with diarrhea: Report of a case due to diffuse hyperplasia of no beta islet tissue with a review of 54 additional cases. Arch Intern Med 1974; 1974: 133.
21. Stacpoole PW. The glucagonoma syndrome: Clinical features, diagnosis, and treatment. Endocr Rev 1981; 2: 347.
22. Holst JJ. Glucagon-producing tumors. In Cohen S, Soloway D (eds): Hormone Producing Tumors of the Gastrointestinal Tract. New York: Churchill Livingstone 1985; 57.
23. Krejs GJ, Ocri L, Conlon M et al. Somatostatinoma syndrome (biochemical, morphological, and clinical features). N Engl J Med 1979; 301: 285.
24. Eckhauser FE, Cheung PS, Vinik AI et al. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 1986; 100: 978.
25. Solcia E, Capella C, Fiocca R et al. The gastroenteropancreatic endocrine system and related tumors. Gastroenterol Clin North Am 1989; 18(4): 671-93.
26. Rindi G, Luinetti O, Cornaggia M et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma. A clinicopathologic study. Gastroenterol 1993; 104: 994-1006.
27. Spread C, Berkel H, Jewell L et al. Colon carcinoid tumors. A population-based study. Dis Colon Rectum 1994; 37: 482-91.
28. Moertel CG, Sauer WG, Dockerty MB et al. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901-12.
29. Pearse AGE. The APUD cell concept and its implications in pathology. In Sommers SC (ed): Pathology Annual. New York: Appleton Century Crofts 1974; 27-41.
30. Creutzfeldt W, Arnold R, Frerichs H. Insulinoma and gastrinomas. In Bloom SR, Polar JM (eds): Gut Hormones. New York: Churchill Livingstone, 1978; 589-98.
31. Vance JE, Stoll RW, Kitabuchi AE et al. Familial neisidioblastosis as the predominant manifestations of multiple endocrine adenomatosis. Am J Med 1972; 52: 211-27.
32. Chaudhry A, Gobl A, Eriksson B et al. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res 1994; 54: 981-6.
33. 3 gene located in the MEN-1 region show loss of expression in endocrine tumours. Hum Mol Genet 1994; 3: 1775-81.
34. Chaudhry A, Öberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumor Biol 1992; 13: 27-35.
35. Henriksen R, Funa K, Wilander E et al. Expression and prognostic significance of platelet-derived growth factor and its receptor in epithelial ovarian neoplasms. Cancer Res 1993; 53: 4550-4.
36. Tsushima K, Nagorney DM, Weiland LH et al. The relationship of low cytometry DNA analysis and clinicopathology in small-intestinal carcinoids. Surgery 1989; 105: 366.
37. Costes V, Marty-Ané C, Piccot MC et al. Typical and atypical bronchopulmonary carcinoid tumors: A clinicopathologic and KI-67-labeling study. Human Pathol 1995; 26: 740-5.
38. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145-51.
39. Stridsberg M, Öberg K, Li Q et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49-59.
40. Tiensuu Janson E. Carcinoid tumours. Clinical aspects and the use of somatostatin analogues for characterization and treatment. Acta Universitatis Upsaliensis. Comprehensive summaries of Uppsala dissertations from the Faculty of Medicine 1995; 551.
41. McGuigin JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterol 1989; 79: 1324-7.
42. Skogseid B, Öberg K, Benson L et al. A standardized meal stimulation test of endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type I syndrome. Five years' experience. J Clin Endocrinol Metab 1987; 64: 1233-40.
43. Norheim I, Theodorsson-Norheim E, Brodin E et al. Tachykinins in carcinoid tumors: Their use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metabol 1986; 63: 605-12.
44. Lackey BM, Fishman EK, Jones B et al. Computed tomography of abdominal carcinoid tumors. J Comput Assist Tomogr 1985; 9: 38.
45. Stark DD, Moss AA, Goldberg HI et al. Computed tomography and nuclear magnetic resonance imaging of pancreatic islet cell tumors. Surgery 1983; 94: 1024.
46. Vinik AI, Delbridge L, Moattari R et al. Transhepatic portal vein catherization for localization of insulinomas: A tenyear experience. Surgery 1991; 109: 1.
47. Kwekkeboom DJ, Krenning EP, Bakker WH et al. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993; 20: 283-92.
48. 1]Octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994; 131: 577-81.
49. Rösch T, Lightdale MD, Bolet JF et al. Localization of pancreatic endocrine tumours by endoscopic ultrasonography. N Engl J Med 1992; 326: 1721-6.
50. Eriksson B, Bergström M, Lilja A et al. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 1993; 32: 189-96.
51. Makridis C, Öberg K, Juhlin C et al. Surgical treatment of midgut carcinoid tumors. World J Surg 1990; 14: 377.
52. Thompson GB, van Heerden JA, Martin JK et al. Carcinoid tumors of the gastrointestinal tract: Presentation, management and prognosis. Surgery 1985; 98: 1054.
53. Arunha GU, Greenlee HB. Surgical management of carcinoid tumors of the gastrointestinal tract. Ann Surg 1980; 41: 429.
54. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: Results of a 10-year prospective study. Ann Surg 1992; 215: 8.
55. Norton JA, Doppman JL, Gardner JD et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986; 203: 352-9.
56. Starzl T. Abdominal organ cluster transplantation for the treatment of upper abdominal malignancy. Ann Surg 1989; 210: 374-6.
57. Thompson NW, Bondeson AG, Bondeson L et al. The surgical treatment of gastrinoma in MEN 1 syndrome patients. Surgery 1989; 106: 1081-5.
58. Norton JA, Jensen RT. Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome. World J Surg 1991; 15: 151-9.
59. Shupak KP, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991; 20: 489.
60. Keane TS, Rider WP, Harwood HR et al. Whole body radiation in the management of the metastatic carcinoid tumor. Int J Radiat Oncol Biol Phys 1981; 7: 1519.
61. 125I-MIBG therapy of carcinoid tumor of intestinal origin. Eur J Nucl Med 1988; 14: 234.
62. 125I-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 1987; 13: 187.
63. Stockman F, von Tomatowski HJ, Reimold WV et al. Hepatic artery embolization for treatment of endocrine gastrointestinal tumors with metastases. Gastroenterol 1984; 22: 652.
64. Marlink RG, Lakich JJ, Robins JR et al. Hepatic arterial embolization of metastatic hormone secreting tumors. Cancer 1991; 65: 2227.
65. Moertel CG, Johnson CM, McKusick MA et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Int Med 1994; 120: 302-9.
66. Venook A, Stagg R, Frye J et al. Chemoembolization of patients with liver metastases from carcinoid and islet cell tumors. Proc Am Soc Clin Oncol 1991; 10: 386 (Abstr).
67. Goodwin JD. Carcinoid tumors: An analysis of 2837 cases. Cancer 1975; 36: 560-9.
68. Zeitels J, Naunheim K, Kaplan EL et al. Carcinoid tumors. A 37-year experience. Arch Surg 1982; 117: 732-7.
69. Broder LE, Carter SK. Pancreatic islet cell carcinoma. Results of therapy with streptozocin in 52 patients. Ann Intern Med 1973; 79: 108-18.
70. Altimari A, Badrinath K, Reisel H et al. DTIC therapy in patients with malignant intraabdominal neuroendocrine tumors. Surgery 1987; 102(6): 1009-17.
71. Eriksson B, Skogseid B, Lundqvist G. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990; 65: 1883-90.
72. Moertel CG, Lavin P, Hahn G. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1982; 66: 1567-9.
73. Moertel CG, Hanley JA, Johnsson LA. Streptozocin alone compared with Streptozocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980; 303: 1189-94.
74. Moertel CG, Lefkopoulo M, Lipsitz M. Streptozocin-doxorubicin, streptozocin-flourouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-23.
75. von Schrenck T, Howard J, Doppman J. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterol 1988; 94: 1326-34.
76. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727-40.
77. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2: 327-34.
78. van Hazel GA, Rubin J, Moertel CG. Treatment of metastatic carcinoid tumor with dactinomycin or dacarbacine. Cancer Treat Rep 1983; 67: 583-5.
79. Moertel CG, Rubin J, O'Connell MJ. Phase II study of Cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Tret Rep 1986; 70: 1459-60.
80. Weiss RB. Streptozotocin: A review of its pharmacology, efficacy and toxicity. Cancer Treat Rep 1982; 66: 427-38.
81. Murray-Lyon IM, Eddelston ALWF, Williams R et al. Treatment of multiple hormone-producing malignant islet cell tumors with Streptozotocin. Lancet 1968; ii: 895-8.
82. Norheim I, Öberg K, Alm G. Treatment of malignant carcinoid tumors; a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol 1989; 25. 1475-9.
83. Schein PS, O'Connell MJ, Blom J et al. Clinical antitumor activity and toxicity of Streptozotocin. Cancer 1974; 34: 993-1000.
84. Moertel CG, O'Connell M, Reitemeier RJ et al. An evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat Rep 1984; 68: 665-7.
85. Bukowski RM, Stephens R, Oishi N et al. Phase II trial of 5-FU, adriamycin, cyclophosphamide, and Streptozotocin (FAC-S) in metastatic carcinoid. Proc Am Soc Clin Oncol 1983; 2: 130.
86. Chernicoff D, Bukowski RM, Groppe CW et al. Combination chemotherapy for islet carcinoma and metastatic carcinoid tumors with 5-FU and Streptozotocin. Cancer Treat Rep 1979; 63: 795-6.
87. Engström P, Lavin P, Folsch E et al. Streptozotocin (STZ) + fluorouracil (FU) vs. Adriamycin (AD) for metastatic carcinoid tumors. Proc Am Ass Cancer Res 1983; 24: 551.
88. Engström PF, Lavin PT, Folsch E et al. Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumors. J Clin Oncol 1984; 2: 1255-9.
89. Kelsen DP, Cheng E, Kemeny N et al. Streptozotocin and Adriamycin in the treatment of apud tumors (carcinoid, islet cell and medullary carcinomas of the thyroid). Proc Am Ass Cancer Res 1982; 23: 433.
90. Bukowski RM, Johnsson KG, Peterson RF et al. A phase II trial combination chemotherapy in patients with metastatic carcinoid tumors: A Southwest Oncology Group study. Cancer 1987; 60: 2891.
91. Moertel CG, Kvols LK, O'Connell MJ et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32.
92. Reichlin D. Somatostatin. N Engl J Med 1983; 309: 1495-501, 1556-63.
93. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrine Rev 1995; 16: 427-42.
94. Yajima Y, Akita Y, Saito T. Pertussis toxin blocks the inhibitory effects of somatostatin on cAMP-dependent vasoactive intestinal peptide and CAMP-independent thyrotropin releasing hormone-stimulated prolactin secretion of GH3 cells. J Biol Chem 1986; 261: 2684-9.
95. 2+ channels in beta cell. J Biol Chem 1991; 266: 837-43.
96. Liebow C, Lee MT, Schally A. Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. Metabolism 1990; 39: 163-6.
97. Dunne MJ, Elton R, Fletcher T et al. Somatostatin and gastroenteropancreatic endocrine tumors - therapeutic characteristics. In O'Dorisio TM (ed): Somatostatin in the Treatment of GEP Endocrine Tumors. Berlin: Springer-Verlag 1989.
98. Kvols LK, Moertel CG, O'Connell MJ et al. Treatment of the malignant carcinoid evaluation of a long-acting somatostatin analog. N Engl J Med 1986; 315: 663-6.
99. Vinik AL, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989; 34: 14S-27S.
100. Öberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumors with a long-acting somatostatin analog octreotide. Acta Oncol 1991; 4: 503-7.
101. O'Dorisio TM, Gaginella TS, Mekhijian HS et al. Somatostatin and analogs in the treatment of VIPoma. Ann NY Acad Sci 1988; 527: 528-35.
102. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 1989; 34: 28S-39S.
103. Öberg K, Funa K, Alm G. Effects of leukocyte interferon upon clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and the carcinoid syndrome. N Engl J Med 1983; 309: 129-33.
104. Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32; 203-8.
105. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989; 7: 865-8.
106. Hanssen LE, Schrumpf E, Kolbenstvedt AN et al. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha-2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24: 787-95.
107. Bartsch HH, Stockmann F, Arnold R et al. Treatment of patients with metastatic carcinoid tumors by recombinant human interferon-alpha-results from a phase II study. J Cancer Res Clin Oncol 1990; 116: 305.
108. Välimäki M, Jarvinen H, Salmela P et al. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991; 67: 547-9.
109. Öberg K, Norheim I, Lind E et al. Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Rep 1986: 70: 1297-304.
110. Öberg K, Alm G, Magnusson A et al. Treatment of malignant carcinoid tumors with recombinant interferon alpha-2b (Intron-A); development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531-5.
111. Schober C, Schuppert F, Schmoll E et al. Interferon alpha-2b in patients with advanced carcinoids and apudomas. Blut (Abstract 34th Ann Congr German Soc Hematol Oncol), 1989; 59: 331.
112. Biesma B, Willemse PHB, Mulder NH et al. Recombinant interferon alpha 2b in patients with metastatic apudomas; effect on tumors and tumor markers. Br J Cancer 1992; 66: 880-5.
113. Tiensuu Janson E, Rönnblom L, Ahlström G et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozotocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 1992; 3: 635-8.
114. Öberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol 1991; 30: 519-22.
115. Jacobsen MB, Hanssen LE, Kolmanskog F et al. The effect of interferon α-2b treatment with or without prior hepatic artery embolization on clinical response and survival in mid-gut carcinoid patients. Scand J Gastroenterol 1995 (in press).
116. Tiensuu Janson E, Ahlström H, Andersson T et al. Octreotide and Interferon alfa: A new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992; 28A: 1647-50.
117. Funa K, Eriksson B, Wilander E et al. Expression of chromogranin A and B mRNA in carcinoid tumors studied by in situ hybridization. Histochemistry 1991; 95: 555-9.
118. Grandér D, Öberg K, Lundqvist M-L et al. Interferon-induced enhancement of 2′-5′-oligoadenylate synthetase in mid-gut carcinoid tumors. Lancet 1990; 336: 337-40.
119. Andersson T, Wilander E, Eriksson B et al. Effects of interferon on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 1990; 50: 3413-5.